2016, Number 1
PDF size: 196.85 Kb.
ABSTRACTIntroduction: acute lymphoid leukemia (ALL) is the most common malignancy in childhood and it was the first disease treated with a common protocol in Cuba.
Objective: to show therapeutic results achieved at the Instituto de Hematología e Inmunología, La Habana, with protocol ALL-IC BFM 2002 from 2002 to 2008.
Methods and Patients: 125 children treated from January 2002 and December 2011 were included in the study. Patients were classified in prognostic groups according to age at diagnosis, initial leukocyte count, molecular rearrangement studies and response to therapy.
Results: median follow up was 5,8 years; median of age was 5,2 years, and there were more boys than girls with a 1,5/1 ratio. Percentage of ALL of B-cell origin was 81,3 % and TEL-AML1 genetic rearrangement was the most common one with 24,1 %.There were a good response to prednisone prophase in 95,2 % and initial remission was obtained in 91,6 % of the patients and 4% died during the induction phase. Overall survival and event free survival for the whole group after seven years were 74,3 % and 68,9 %, respectively. In standard risk patients results were 84,2 % and 82 %. In Intermediate risk group were 71,8 % and 68,5 %; and in the high risk group were 25,4% for both curves. At the moment of the evaluation 75 % of the patients were in remission.
Conclusions: percentages of overall survival and event free survival were similar to the ones obtained by other centers that use similar protocols elsewhere.
Gandemer V, Auclerc MF, Perel Y, Vannier JP, Le Gall E, Demeocq F, et al. Impact of age, leukocyte count and day 21-bone marrow response to chemotherapy on the long-term outcome of children with Philadelphia chromosome-positive acute lymphoblastic leukemia in the pre-imatinib era: results of the FRALLE 93 study. BMC Cancer. 2009;9:14.
Kamps WA, Bokkerink JP, Hakvoort-Cammel FG, Veerman AJ, Weening RS, van Wering ER, et al. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996). Leukemia. 2002 Jun;16(6):1099-111.
Arico M, Valsecchi MG, Rizzari C, Barisone E, Biondi A, Casale F, et al. Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt- Muenster based chemotherapy. J Clin Oncol. 2008 Jan;26(2):283-9.
Lauter M, Moricke A, Beller R, Zimmermann M, Stamuller M, Helssnter A, et al. Prediction of outcome asessed by early bone marrow response in childhood acute lymphoblastic leukemia treated by ALL BFM 95. Differential effects in precursor B cell and in T cell leukemias. Haematologica. 2012;97(7):1048-56.
Sirvent N, Suciu S, RiallandK, Millot F, Benoit Y, Plantaz D, et al. Prognostic significance ot the initial cerebrospinal fluid (CSF)involvement in children with acute lymphoblastic leukemia (ALL)treated without cranial irradiation Results of the European Organization for Research and Treatment of Cancer (EORTC) Children Leukemia Group Study 5888. Eur J Cancer. 2011;67(2):289-47.
Ribera JM, Oriol A, Gonzalez M, Vidriales B, Brunet S, Esteve J, et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Haematologica. 2010 Jan;95(1):87-95.
Manabe A, Ohara A, Hasegawa D, Tsuchida M, Kumagai M, Shimada H, et al. Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group Study L99-15. Haematologica. 2008 May;93(8):1155-60.
Ribera JM, Oriol A, Morgades M, Montesino S, Perma J, Gonzalez-Campos J, et al. Treatment of high risk Philadelphia chromosome negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry. Final results of the PETHEMA ALL-AR-93 trial. J Clin Oncol. 2014;32(15):1595-604.
Tallen G, Ratei R, Mann G, Kaspers G, Niggli F, Karachunsky A, et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol. 2010 May;28(14):2339-47.
Pastorczak AF, Fendler W, Zalewska-Szewckyk B, Gomiak P, Neiman M, Trelwska J, et al. Polish Pediatric Leukemia/Lymphoma Study Group. Asparagine synthetase (ASNS) gene polymorphim is associated with the outcome of childhood acute lymphoblastic leukemia affecting early response to treatment. Leuk Res. 2014 Feb;38(2):160-3.
Talen G, Patel R, Mann G, Kaspers G, Niggl F, Karachuns A, et al. Long-term outcomes in children with relapsed acute lymphoblastic leukaemia after time-point and site of relapse stratification and intensified short courses of multidrug chemotherapy. Results of ALL-REZ BFM 90. J Clin Oncol. 2010;28(14):2339-47.
Klingebiel T, Cornish J, Labopin M, Locatelli F, Darbyshire P, Handgretinger R, et al. Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group. Blood. 2010 Apr 29;115(17):3437-46.